Compare Medpace Holdings Inc (MEDP) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs BlackRock TCP Capital Corp — how do they compare? Medpace Holdings Inc trades at $532.89 (market cap $15.08B), while BlackRock TCP Capital Corp trades at $3.24 (market cap $270.17M). The key difference: Medpace Holdings Inc is far larger — about 55.8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 26.09% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | TCPC | |
|---|---|---|
Market Cap | $15.08B | $270.17M |
Sector | Technology | Financials |
52-Week High | $620.59 | $7.64 |
52-Week Low | $308.88 | $3.14 |
Enterprise Value | $14.55B | — |
Dividend Yield | — | 26.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
TCPC trades at $3.21, down 3.02% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025, though it maintains a 112% net income margin due to accounting adjustments. Recent news includes a Zacks upgrade to Buy and an upcoming Q2 2026 earnings report on August 6, 2026.
Outlook remains cautious with mixed analyst sentiment (30.77% Buy) and ongoing legal scrutiny. The stock's low P/B of 0.49 suggests potential value, but persistent losses and negative cash flow pose significant risks. Dividend sustainability is a key concern amid financial pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
